The EU's first migraine drug with both curative/preventive action!

CompilationFan Dongdong

Recently, Vydura (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist developed by Pfizer and Biohaven, received marketing authorization from the European Commission (EC) for the treatment of acute migraine with or without aura, and Prevention of adult-onset migraine headaches with at least 4 attacks per month

Globally, migraine affects women three to four times more than men, and in Europe alone about one in 10 people suffer from migraines

Results of a phase 3 study previously published in The Lancet showed that a single dose of rimegepant reduced pain and improved migraine-related symptoms within two hours compared to a placebo

rimegepant is a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, which was launched in the United States in February 2020.

This time, rimegepant was finally approved for marketing in Europe, following the approval recommendation made by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in February

Reference source: Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine